Prevention of Cerebral Palsy in preterm labour
PReCePT was developed by the West of England AHSN in collaboration with University Hospitals Bristol NHS Foundation Trust and involved both patients and staff. This evidence-based, cost-effective project was designed to help reduce cerebral palsy in babies through the increased antenatal administration of magnesium sulphate (MgSO4) to mothers during preterm labour, costing from £1 per individual dose.
The intervention was adopted by all five maternity units in the West of England. Since the launch of the project in August 2014, phase one of PReCePT has prevented seven cases of cerebral palsy across the region.
Successful scaling up of PReCePT is likely to prevent several hundred cases of cerebral palsy per year, based on highest grade evidence. The project is led by the West of England AHSN working in partnership with all 15 AHSNs across the country, and aligns with the Maternal and Neonatal Health Safety Collaborative (MNHSC) change drivers and the national Patient Safety Collaboratives (PSCs).
PReCePT spread and adoption is also running in tandem with the PReCePT Study; a research trial nested within the national programme funded by the Health Foundation. It aims to assess the effectiveness of two different quality improvement approaches in implementing the project across a subset of maternity units. Of the 152 maternity units across England in the PReCePT Programme, 40 maternity units have been randomly selected to be part of the PReCePT study. Within this group, 13 units are receiving enhanced QI support from the Study team, and 27 units are being observed while implementing the standard QI support model.
PReCePT is one of the national programmes the AHSN supports - see more details on our dedicated PReCePT web page.
If you'd like to discuss this Innovation, have an idea or a new Innovation, please get in touch.